Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

TKM 130803

Next Previous
Drug Profile

TKM 130803

Alternative Names: siEbola-3 - Arbutus Biopharma; TKM-130803; TKM-Ebola-Guinea

Latest Information Update: 29 Oct 2016

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Tekmira Pharmaceuticals Corporation
  • Developer Arbutus Biopharma; University of Oxford
  • Class Antineoplastics; Small interfering RNA
  • Mechanism of Action RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Suspended Ebola virus infections

Most Recent Events

  • 25 Oct 2016 Suspended - Phase-II for Ebola virus infections in Sierra Leone (IV, Infusion) (Arbutus Biopharma pipeline; October 2016)
  • 25 Oct 2016 Efficacy and safety data from the phase II RAPID-TKM trial in Ebola virus infections released by Arbutus Biopharma
  • 19 Apr 2016 Arbutus Biopharma terminates the phase II RAPID-TKM trial in Ebola virus infections in Sierra Leone due to futility rule (IV, Infusion)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top